OpenAI Mass-Produces Its In-House AI Chips! Worldcoin Price Skyrockets to One-Month High!
TradingKey – OpenAI announced mass production of its self-developed AI chips and the launch of an AI-driven recruitment platform, boosting the WLD token’s price for a fourth consecutive day.
On Monday (September 8), Worldcoin (WLD) extended its rally, surging over 14% to decisively break above $1.10 — its highest level since July 28.
Worldcoin Price Chart, Source: CoinMarketCap
Since September 5, driven by a series of positive announcements from OpenAI, Worldcoin’s price has climbed for four straight days, gaining 32% in total.
Worldcoin Price Chart, Source: TradingView
Last Friday, OpenAI revealed a partnership with Broadcom (AVGO) to mass-produce its in-house AI chips and unveiled an AI-powered recruitment platform. The company also projected nearly $10 billion in ChatGPT-driven revenue this year.
Related Articles
Japan Q2 GDP Commentary: Growth Revised Upward, Yen May Rise
TradingKey - On 8 September 2025, Japan released the revised Q2 GDP figures. The data showed that real GDP grew by 0.5% quarter-on-quarter, surpassing market expectations of 0.3% and the previous quarter’s 0% growth.
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks ahead
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”
TradingKey - 5 companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8, with a total expected fundraising exceeding $3 billion, making it the busiest IPO week of 2025. Investors are closely watching the debut performance of Klarna, Gemini, and Figure.
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
